Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient \>40 years~2. Written informed consent signed prior to entry into the study~3. IPF diagnosed (according to ATS / ERS criteria) less than 5 years prior to screening visit.~4. HRCT within 12 months of randomisation and biopsy (the latter if needed to fulfil ATS/ERS criteria) centrally reviewed and consistent with diagnosis.~5. FVC\>50 % of predicted value~   Predicted normal values will be calculated according to ESCS (R94-1408):~   Males :~   FVC predicted (L) = 5.76 x height (meters)- 0.026 x age (years) -4.34~   Females :~   FVC predicted (L) = 4.43 x height (meters)- 0.026 x age (years) -2.89~6. Single breath DLCO (corrected for Hb) 30 - 79% inclusive of predicted .~   Different sites may use different prediction formulas, based on the method used to measure DLco. In any case, the method used must be in compliance with the ATS/ERS guideline on DLCO measurements (R06-2002), and the prediction formula appropriate for that method. Raw data (gas mixture, equation used for prediction of normal, further adjustments made if so) must be traced.~   Adjustment for haemoglobin (R06-2002):~   Males :~   DLCO predicted for Hb = DLCO predicted x (1.7Hb/\[10.22+Hb\])~   Females :~   DLCO predicted for Hb = DLCO predicted x (1.7Hb/\[9.38+Hb\]) where Hb is expressed in g/dL-1~7. PaO2 \>= 55 mmHg (sea level to 1500 m) or 50 mmHg (above 1500 m) room air~Exclusion Criteria:~1. AST, ALT \> 1.5 x ULN ;~2. Bilirubin \> 1.5 x ULN~3. Relevant airways obstruction~4. Continuous oxygen supplementation at randomisation (defined as \> 15 hours supplemental oxygen per day).~5. Active infection at screening or randomisation.~6. Neutrophils \< 1500 / mm3~7. International normalised ratio (INR) \> 1.5 and/or Partial thromboplastin time (PTT) \> 1.5 x ULN ;~8. Platelets \< 100 000 /mL~9. Haemoglobin \< 9.0 g/dL~10. In the opinion of the Investigator, patient is likely to have lung transplantation during study~11. Life expectancy for disease other than IPF \< 2.5 years (Investigator assessment).~12. Other disease that may interfere with testing procedures or in judgement of Investigator may interfere with trial participation or may put the patient at risk when participating to this trial.~    * Myocardial infarction during the previous 6 months~   * Unstable angina during the previous month~13. Other investigational therapy received within 8 weeks prior to screening visit.~14. Pregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of birth control for at least one month prior to enrolment.~15. Sexually active males not committing to using condoms during the course of the study (except if their partner is not of childbearing potential).~16. Known or suspected active alcohol or drug abuse.~17. Bleeding risk : Known inherited predisposition to bleeding, patients who require full-dose anticoagulation, Patients who require full-dose antiplatelet therapy, History of hemorrhagic CNS event within 12 months prior to screening , Any of the following within 3 months prior to screening : Gross / frank haemoptysis or haematuria, Active gastro-intestinal bleeding or ulcers, Major injury or surgery~18. Thrombotic risk~19. Surgical procedures planned to occur during trial period.~20. Coagulopathy~21. Uncontrolled systemic arterial hypertension~22. known hypersensitivity to lactose or any component of the study medication

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dose 1 (Type: EXPERIMENTAL): low dose BIBF1120 once daily
- dose 2 (Type: EXPERIMENTAL): low dose BIBF 1120 twice daily
- dose 3 (Type: EXPERIMENTAL): intermediate dose BIBF 1120 twice daily
- dose 4 (Type: EXPERIMENTAL): high dose BIBF 1120 twice daily
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).